Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

New method for mapping myelin sheaths of nerve cells

Researchers including members from the Niels Bohr Institute at the University of Copenhagen have developed a new method for making detailed X-ray images of brain cells.

13 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Adherence to disease-modifying drugs is low in patients with multiple sclerosis

Disease-modifying drugs (DMDs) are injected medications used to slow the progression of multiple sclerosis, and have been shown to reduce the frequency and severity of relapses. But according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences, adherence to all DMDs is low, with less than half of patients, or 44 per cent, continually adherent after two years.

11 May 2011

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

While many 16-year-olds are content with PlayStation, Toronto-area student Marshall Zhang used the Canadian SCINET supercomputing network to invent a new drug cocktail which could one day help treat cystic fibrosis.

11 May 2011

EMA agrees to Swedish Orphan Biovitrum, Biogen Idec's pediatric rFIXFc trial in hemophilia

Biogen Idec and Swedish Orphan Biovitrum today announced that the European Medicines Agency's Pediatric Committee has adopted an opinion agreeing to the pediatric investigational plan for the companies' long-lasting, fully-recombinant Factor IX Fc fusion protein.

9 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

New genetic discovery in megalencephalic leukoencephalopathy with subcortical cysts

White matter disease covers a large group of disorders that affect the white matter, or myelin. In children these disorders are commonly genetic and often go undiagnosed. In new research, a team led by Raúl Estévez, a lecturer from the Department of Physiological Sciences II, based at the UB's Bellvitge Health Sciences Campus, working with the researcher Marjo van der Knaap, from the University Medical Centre at VU University Amsterdam, have identified mutant GLIALCAM as responsible for 25% of cases of megalencephalic leukoencephalopathy with subcortical cysts, a rare genetic disease affecting cerebral myelin.

4 May 2011

Obesity during middle age may increase risk of developing dementia

According to a new study, being overweight or obese during middle age may increase the risk of certain dementias.

3 May 2011

Aquaporin-4 plays a key role in brain inflammation

A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.

3 May 2011

Grant Thornton Leader & Innovator of the Year award for Diplomat Specialty Pharmacy president

Phil Hagerman, president and CEO of Diplomat Specialty Pharmacy in Flint, has been named Grant Thornton Leader & Innovator of the Year.

30 Apr 2011

ETP makes investment to support development of ICVrx's targeted epilepsy drug technology

Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.

30 Apr 2011

Drug subsidy issues out of PBS’ hands - almost

According to Health Minister Nicola Roxon, expensive drugs have never been automatically listed for subsidy and they can't be now when the government controlling expenses. She added that federal Labor has to balance competing priorities in health and every other department.

29 Apr 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene Corporation: “The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success”.

28 Apr 2011

Researchers discover molecular mechanisms behind autoimmunity

Researchers from Boston University School of Medicine have discovered that human proteins with an affinity for Dermatan Sulfate have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DS-autoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models.

26 Apr 2011

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.

25 Apr 2011

GM-CSF appears to be key culprit in multiple sclerosis onset

Reporting in Nature Immunology, Jefferson neuroscientists have identified a driving force behind autoimmune diseases such as multiple sclerosis, and suggest that blocking this cell-signaling molecule is the first step in developing new treatments to eradicate these diseases.

25 Apr 2011

Study shows neutralizing antibodies against GM-CSF can halt MS development

The neutralization of the cytokine GM-CSF could halt the development of multiple sclerosis. This was demonstrated by the research team of the immunologist Burkhard Becher at the University of Zurich in an animal model.

25 Apr 2011

Teva acknowledges promising results of DEFINE study in MS

We acknowledge the results of the DEFINE study seem promising for patients. It is important to note that as a general rule, results obtained in clinical trials in multiple sclerosis (MS) cannot be compared, unless agents are tested in a head-to-head manner in the same trial.

22 Apr 2011

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed U.S. neurologists selected Biogen Idec/Elan's Tysabri as the most effective therapy for the treatment of relapsing-remitting multiple sclerosis, when compared to other currently available agents.

22 Apr 2011

Researchers reveal how immune system distinguishes between beneficial and pathogenic organisms

The human gut is filled with 100 trillion symbiotic bacteria-ten times more microbial cells than our own cells-representing close to one thousand different species. "And yet, if you were to eat a piece of chicken with just a few Salmonella, your immune system would mount a potent inflammatory response," says Sarkis K. Mazmanian, assistant professor of biology at the California Institute of Technology (Caltech).

22 Apr 2011

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

New method for mapping myelin sheaths of nerve cells

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Adherence to disease-modifying drugs is low in patients with multiple sclerosis

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

EMA agrees to Swedish Orphan Biovitrum, Biogen Idec's pediatric rFIXFc trial in hemophilia

Acorda reports $0.7 million GAAP net loss for first quarter 2011

New genetic discovery in megalencephalic leukoencephalopathy with subcortical cysts

Obesity during middle age may increase risk of developing dementia

Aquaporin-4 plays a key role in brain inflammation

Grant Thornton Leader & Innovator of the Year award for Diplomat Specialty Pharmacy president

ETP makes investment to support development of ICVrx's targeted epilepsy drug technology

Drug subsidy issues out of PBS’ hands - almost

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Researchers discover molecular mechanisms behind autoimmunity

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

GM-CSF appears to be key culprit in multiple sclerosis onset

Study shows neutralizing antibodies against GM-CSF can halt MS development

Teva acknowledges promising results of DEFINE study in MS

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Researchers reveal how immune system distinguishes between beneficial and pathogenic organisms

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in